CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group
Copyright policy )CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group
In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lymphomas. In a secondary analysis we evaluated the impact of adding rituximab to CEOP-14/CEOP-21 chemotherapy.The trial opened in March 1999, and patients were randomly assigned to either CEOP-14 or CEOP-21. All patients enrolled from May 2002 onward received rituximab with each chemotherapy cycle, and those attaining a complete response received rituximab consolidation.Complete and overall response rates in the CEOP-21 +/- rituximab (N = 114) and CEOP-14 +/- rituximab (N = 103) arms were similar, as were the overall survival (P = 0.769) and time to progression distributions (P = 0.969). Rituximab was shown to have a beneficial effect both on the overall survival and on the time to progression.Thus far, no significant improvement in outcome has been demonstrated with CEOP-14 +/- rituximab versus CEOP-21 +/- rituximab. However, with addition of rituximab to CEOP-21/CEOP-14, significant improvements in time to progression and overall survival were achieved.
- Aristotle University of Thessaloniki Greece
- Yale University United States
- Democritus University of Thrace Greece
- University of Ioannina Greece
- National and Kapodistrian University of Athens Greece
Male, B-cell, Lymphoma, Mantle-Cell, Treatment response, Lymphoma, B-Cell/drug therapy/pathology, Cancer growth, Multiple cycle treatment, Phase 3 clinical trial, Prednisone/adverse effects/therapeutic use, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Pathology, Treatment outcome, Aged, 80 and over, Antibodies, Monoclonal, Multicenter study, Clinical trial, Antineoplastic agent, Randomized controlled trial, Vincristine, Nonhodgkin lymphoma, Drug dose reduction, Infection, Rituximab, Human, Cyclophosphamide/adverse effects/therapeutic use, Diarrhea, Lymphoma, B-Cell, Febrile neutropenia, Major clinical study, Lymphoma, T-Cell, Antibodies, Monoclonal/administration & dosage, Article, Health Sciences, Vincristine/adverse effects/therapeutic use, Humans, Cyclophosphamide, Aged, Recombinant granulocyte colony stimulating factor, Leukopenia, Cardiotoxicity, Cancer combination chemotherapy, B cell lymphoma, Επιστήμες Υγείας, Comparative study, Vincristine sulfate, Ceop protocol 1, Lymphoma, Mantle-Cell/drug therapy/pathology, Lymphoma, Unclassified drug, T cell lymphoma, Antibodies, Monoclonal, Murine-Derived, T-cell, Controlled clinical trial, Nausea and vomiting, Deep vein thrombosis, Monoclonal, Lymphoma, T-Cell/drug therapy/pathology, Overall survival, Middle aged, Fatigue, Priority journal, Drug withdrawal, Lymphoma, Non-Hodgkin/*drug therapy/pathology, Lymphoma, Non-Hodgkin, Doseintensification, Anemia, Brain hemorrhage, Middle Aged, Anorexia, Female, Drug hypersensitivity, Monoclonal antibody, Adult, Neutropenia, Fever, Aggressive non-hodgkin lymphoma, Adolescent, Liver toxicity, Antibodies, Mucosa inflammation, Antineoplastic combined chemotherapy protocols, Neurotoxicity, Drug dose comparison, Ceop, Epirubicin, Non-hodgkin, Mantle cell lymphoma, Alopecia, Thrombocytopenia, Epirubicin/adverse effects/therapeutic use, Mantle-cell, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Prednisone, Controlled study
Male, B-cell, Lymphoma, Mantle-Cell, Treatment response, Lymphoma, B-Cell/drug therapy/pathology, Cancer growth, Multiple cycle treatment, Phase 3 clinical trial, Prednisone/adverse effects/therapeutic use, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Pathology, Treatment outcome, Aged, 80 and over, Antibodies, Monoclonal, Multicenter study, Clinical trial, Antineoplastic agent, Randomized controlled trial, Vincristine, Nonhodgkin lymphoma, Drug dose reduction, Infection, Rituximab, Human, Cyclophosphamide/adverse effects/therapeutic use, Diarrhea, Lymphoma, B-Cell, Febrile neutropenia, Major clinical study, Lymphoma, T-Cell, Antibodies, Monoclonal/administration & dosage, Article, Health Sciences, Vincristine/adverse effects/therapeutic use, Humans, Cyclophosphamide, Aged, Recombinant granulocyte colony stimulating factor, Leukopenia, Cardiotoxicity, Cancer combination chemotherapy, B cell lymphoma, Επιστήμες Υγείας, Comparative study, Vincristine sulfate, Ceop protocol 1, Lymphoma, Mantle-Cell/drug therapy/pathology, Lymphoma, Unclassified drug, T cell lymphoma, Antibodies, Monoclonal, Murine-Derived, T-cell, Controlled clinical trial, Nausea and vomiting, Deep vein thrombosis, Monoclonal, Lymphoma, T-Cell/drug therapy/pathology, Overall survival, Middle aged, Fatigue, Priority journal, Drug withdrawal, Lymphoma, Non-Hodgkin/*drug therapy/pathology, Lymphoma, Non-Hodgkin, Doseintensification, Anemia, Brain hemorrhage, Middle Aged, Anorexia, Female, Drug hypersensitivity, Monoclonal antibody, Adult, Neutropenia, Fever, Aggressive non-hodgkin lymphoma, Adolescent, Liver toxicity, Antibodies, Mucosa inflammation, Antineoplastic combined chemotherapy protocols, Neurotoxicity, Drug dose comparison, Ceop, Epirubicin, Non-hodgkin, Mantle cell lymphoma, Alopecia, Thrombocytopenia, Epirubicin/adverse effects/therapeutic use, Mantle-cell, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Prednisone, Controlled study
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).16 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!